TY - JOUR
T1 - Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
AU - Srinivasan, Ramaprasad
AU - Daniels, Jasmine
AU - Fusaro, Vincent
AU - Lundqvist, Andreas
AU - Killian, Jonathan K.
AU - Geho, David
AU - Quezado, Martha
AU - Kleiner, David
AU - Rucker, Sally
AU - Espina, Virginia
AU - Whiteley, Gordon
AU - Liotta, Lance
AU - Petricoin, Emmanuel
AU - Pittaluga, Stefania
AU - Hitt, Ben
AU - Barrett, A. J.
AU - Rosenblatt, Kevin
AU - Childs, Richard W.
PY - 2006/6
Y1 - 2006/6
N2 - Objective: The rapid diagnosis of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT) is important for optimizing the management of this life-threatening complication. Current diagnostic techniques are time-consuming and require invasive tissue sampling. We investigated serum protein pattern analysis using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry as a tool to diagnose GVHD. Patients and Methods: Eighty-eight serum samples were obtained from 34 patients undergoing HCT either pretransplant (n = 28 samples) or at various time points posttransplant (n = 60 samples), including 22 samples obtained on the day of onset of acute GVHD symptoms. Serum proteomic spectra generated from a "training set" of known samples were used to identify distinct proteomic patterns that best categorized a sample as either pretransplant, posttransplant non-GVHD, or GVHD; these distinct proteomic signatures were subsequently used to classify samples from a masked "test" sample set into the appropriate diagnostic category. Results: Proteomic pattern analysis accurately distinguished GVHD samples from both posttransplant non-GVHD samples and pretransplant samples (100% specificity and 100% sensitivity in both cases). Furthermore, distinct serum proteomic signatures were identified that distinguished pretransplant from posttransplant non-GVHD samples (100% specificity and 94% sensitivity). Conclusion: These preliminary data suggest a potential application of SELDI-TOF-based proteomic analysis as a rapid and accurate method to diagnose acute GVHD.
AB - Objective: The rapid diagnosis of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT) is important for optimizing the management of this life-threatening complication. Current diagnostic techniques are time-consuming and require invasive tissue sampling. We investigated serum protein pattern analysis using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry as a tool to diagnose GVHD. Patients and Methods: Eighty-eight serum samples were obtained from 34 patients undergoing HCT either pretransplant (n = 28 samples) or at various time points posttransplant (n = 60 samples), including 22 samples obtained on the day of onset of acute GVHD symptoms. Serum proteomic spectra generated from a "training set" of known samples were used to identify distinct proteomic patterns that best categorized a sample as either pretransplant, posttransplant non-GVHD, or GVHD; these distinct proteomic signatures were subsequently used to classify samples from a masked "test" sample set into the appropriate diagnostic category. Results: Proteomic pattern analysis accurately distinguished GVHD samples from both posttransplant non-GVHD samples and pretransplant samples (100% specificity and 100% sensitivity in both cases). Furthermore, distinct serum proteomic signatures were identified that distinguished pretransplant from posttransplant non-GVHD samples (100% specificity and 94% sensitivity). Conclusion: These preliminary data suggest a potential application of SELDI-TOF-based proteomic analysis as a rapid and accurate method to diagnose acute GVHD.
UR - http://www.scopus.com/inward/record.url?scp=33646682175&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2006.02.013
DO - 10.1016/j.exphem.2006.02.013
M3 - Article
C2 - 16728285
AN - SCOPUS:33646682175
SN - 0301-472X
VL - 34
SP - 796
EP - 801
JO - Experimental Hematology
JF - Experimental Hematology
IS - 6
ER -